Tower Research Capital (TRC)’s Titan Pharmaceuticals TTNP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-469
| Closed | -$2.25K | – | 5608 |
|
|
2025
Q3 | $2.25K | Buy |
+469
| New | +$2.06K | ﹤0.01% | 4663 |
|
|
2024
Q4 | – | Sell |
-743
| Closed | -$3.92K | – | 6009 |
|
|
2024
Q3 | $3.92K | Buy |
743
+26
| +4% | +$149 | ﹤0.01% | 4739 |
|
|
2024
Q2 | $3.99K | Buy |
717
+70
| +11% | +$475 | ﹤0.01% | 4834 |
|
|
2024
Q1 | $4.63K | Buy |
647
+570
| +740% | +$4K | ﹤0.01% | 4654 |
|
|
2023
Q4 | $638 | Sell |
77
-2
| -3% | -$15 | ﹤0.01% | 5519 |
|
|
2023
Q3 | $746 | Hold |
79
| – | – | ﹤0.01% | 5483 |
|
|
2023
Q2 | $1.02K | Sell |
79
-2
| -2% | -$31 | ﹤0.01% | 5497 |
|
|
2023
Q1 | $1K | Hold |
81
| – | – | ﹤0.01% | 5622 |
|
|
2022
Q4 | $1K | Buy |
+81
| New | +$1.53K | ﹤0.01% | 5678 |
|
|
2022
Q2 | – | Sell |
-502
| Closed | -$10K | – | 6526 |
|
|
2022
Q1 | $10K | Buy |
502
+497
| +9,940% | +$10.3K | ﹤0.01% | 4353 |
|
|
2021
Q4 | $0 | Sell |
5
-52
| -91% | -$1.57K | ﹤0.01% | 6570 |
|
|
2021
Q3 | $2K | Buy |
57
+49
| +613% | +$2.15K | ﹤0.01% | 5298 |
|
|
2021
Q2 | $0 | Sell |
8
-333
| -98% | -$16.7K | ﹤0.01% | 5848 |
|
|
2021
Q1 | $20K | Sell |
341
-58
| -15% | -$3.84K | ﹤0.01% | 3891 |
|
|
2020
Q4 | $26K | Buy |
+399
| New | +$31.5K | ﹤0.01% | 3700 |
|
|
2017
Q2 | – | Sell |
-1
| Closed | -$13K | – | 3455 |
|
|
2017
Q1 | $13K | Buy |
+1
| New | +$14.1K | ﹤0.01% | 1608 |
|
|
2016
Q4 | – | Hold |
0
| – | -$2K | – | 4404 |
|
|
2016
Q3 | – | Sell |
-1
| Closed | -$19.4K | – | 3145 |
|
|
2016
Q2 | $10K | Buy |
+1
| New | +$21.3K | ﹤0.01% | 2840 |
|
|
2016
Q1 | – | Sell |
-1
| Closed | -$19K | – | 4941 |
|
|
2015
Q4 | $19K | Buy |
+1
| New | +$16.3K | ﹤0.01% | 1362 |
|
Other funds holding TTNP
CA
GWSA
CSC
DJSG
Tower Research Capital (TRC)'s TTNP Position: Q4 2025 in Review
Tower Research Capital (TRC) sold out of Titan Pharmaceuticals (TTNP) in Q4 2025, closing a stake of 469 shares — an estimated $2.25K sold.
Tower Research Capital (TRC) first reported a position in TTNP in Q4 2015 and held it in 18 quarters. The position peaked at $26K in Q4 2020. 4 funds tracked by Wall St. Rank hold TTNP as of Q4 2025.
- Tower Research Capital (TRC) reported no remaining Titan Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 469 Titan Pharmaceuticals shares in Q4 2025, an estimated $2.25K.
- Tower Research Capital (TRC) first reported a position in Titan Pharmaceuticals in Q4 2015 and held it in 18 quarters.
- Tower Research Capital (TRC)'s Titan Pharmaceuticals position peaked at $26K in Q4 2020.
- 4 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q4 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.